Aquestive director John Cochran acquires 62,229 shares

The shares were transferred to John Cochran by Bratton Capital Management L.P.

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. (AQST) director John Cochran acquired 62,229 common shares on October 21, 2026. He reported direct holdings of 161,715 shares after the transaction. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Other: 62,229 shares

Other 1 txn

Insider Cochran John

Role Director

Type	Security	Shares	Price	Value
Other	Common Stock F1	62,229	$0.00	$0.00

Holdings After Transaction: Common Stock — 161,715 shares (Direct)

Footnotes (1)

1. F1. The shares underlying shares were transferred to John Cochran from Bratton Capital Management L.P.

Key Figures

Shares acquired: 62,229 shares Direct holdings after transaction: 161,715 shares Reported transaction price: 0.0000 per share

3 metrics

Shares acquired 62,229 shares Transferred to John Cochran on October 21, 2026

Direct holdings after transaction 161,715 shares John Cochran's reported holdings after the transfer

Reported transaction price 0.0000 per share Reported for the share transfer

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AQST shares did director John Cochran acquire?

John Cochran acquired 62,229 AQST common shares on October 21, 2026, in a transfer from Bratton Capital Management L.P.

How many AQST shares did John Cochran hold after the transfer?

He reported direct holdings of 161,715 shares after the transfer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 01:39 PM EDT Accepted by SEC EDGAR 10/23/2026 - 01:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cochran John

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

184 LIBERTY CORNER DRIVE, SUITE 305

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2026		J		62,229(1)	A	$0	161,715	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares underlying shares were transferred to John Cochran from Bratton Capital Management L.P.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	10/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)